| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| Gesamt | 1.217.462.122 $ | +200.139.003 $ | +3,9 % | 24 | 1.029.103.106 $ | +60.712.831 $ | +45,8 % | 22 | 969.256.994 $ | +244.234.416 $ | +36,8 % | 21 | |||
| Scholar Rock Holding Corp | SRRK | → 0 | Neutral | 379.370.860 $ | +40.282.288 $ | +11,9 % | 1 | 339.088.572 $ | +35.247.001 $ | +11,6 % | 1 | 303.841.571 $ | +94.817.324 $ | +45,4 % | 1 |
| Mineralys Therapeutics, Inc. | MLYS | → 0 | Schwach | 158.400.066 $ | -645.812 $ | -0,4 % | 1 | 159.045.878 $ | -54.013.365 $ | -25,4 % | 1 | 213.059.243 $ | -24.439.443 $ | -10,3 % | 1 |
| ALUMIS INC. | ALMS | → 0 | Sehr schwach | 178.554.463 $ | +38.769.288 $ | +27,7 % | 1 | 139.785.175 $ | +83.597.011 $ | +148,8 % | 1 | 56.188.164 $ | +37.030.698 $ | +193,3 % | 1 |
| Kalaris Therapeutics, Inc. | KLRS | → 0 | Schwach | 52.426.382 $ | -22.284.045 $ | -29,8 % | 1 | 74.710.427 $ | -34.571.377 $ | -31,6 % | 1 | 109.281.804 $ | +43.111.896 $ | +65,2 % | 1 |
| Septerna, Inc. | SEPN | → 0 | Neutral | 105.464.297 $ | +29.790.751 $ | +39,4 % | 1 | 75.673.546 $ | -12.124.143 $ | -13,8 % | 1 | 87.797.689 $ | +28.562.591 $ | +48,2 % | 1 |
| Alamar Biosciences, Inc. | ALMR | → 0 | Neutral | 67.191.598 $ | +67.191.598 $ | 1 | |||||||||
| SpyGlass Pharma, Inc. | SGP | → 0 | Neutral | 46.967.554 $ | -7.701.328 $ | -14,1 % | 1 | 54.668.882 $ | +54.668.882 $ | 1 | |||||
| Neurogene Inc. | NGNE | → 0 | Neutral | 54.003.644 $ | +19.386.364 $ | +56,0 % | 1 | 34.617.280 $ | -755.536 $ | -2,1 % | 1 | 35.372.816 $ | +5.615.005 $ | +18,9 % | 1 |
| SUTRO BIOPHARMA, INC. | STRO | → 0 | Neutral | 35.287.350 $ | +8.811.208 $ | +33,3 % | 1 | 26.476.142 $ | +24.110.042 $ | +1.019,0 % | 1 | 2.366.100 $ | +458.387 $ | +24,0 % | 1 |
| Inventiva S.A. | IVA | → 0 | Neutral | 23.869.963 $ | -4.961.205 $ | -17,2 % | 1 | 28.831.168 $ | +4.675.325 $ | +19,4 % | 1 | 24.155.843 $ | +24.155.843 $ | 1 | |
| Gossamer Bio, Inc. | GOSS | → 0 | Sehr schwach | 1.188.833 $ | -1.183.778 $ | -49,9 % | 1 | 2.372.611 $ | -20.017.322 $ | -89,4 % | 1 | 22.389.933 $ | +6.267.328 $ | +38,9 % | 1 |
| Upstream Bio, Inc. | UPB | → 0 | Neutral | 2.447.722 $ | -4.176.701 $ | -63,1 % | 1 | 6.624.423 $ | -13.359.253 $ | -66,9 % | 1 | 19.983.676 $ | +1.885.559 $ | +10,4 % | 1 |
| Jade Biosciences, Inc. | JBIO | → 0 | Schwach | 16.359.186 $ | +2.747.574 $ | +20,2 % | 1 | 13.611.612 $ | -1.336.941 $ | -8,9 % | 1 | 14.948.553 $ | +10.364.616 $ | +226,1 % | 1 |
| Aquestive Therapeutics, Inc. | AQST | → 0 | Neutral | 10.400.000 $ | +25.000 $ | +0,2 % | 1 | 10.375.000 $ | -5.775.000 $ | -35,8 % | 1 | 16.150.000 $ | +2.175.000 $ | +15,6 % | 1 |
| Parabilis Medicines, Inc. | PBLS | → 0 | Neutral | 15.218.924 $ | +15.218.924 $ | 1 | |||||||||
| vTv Therapeutics Inc. | VTVT | → 0 | Neutral | 11.238.374 $ | -599.977 $ | -5,1 % | 1 | 11.838.351 $ | -98.504 $ | -0,8 % | 1 | 11.936.855 $ | +3.193.191 $ | +36,5 % | 1 |
| Rani Therapeutics Holdings, Inc. | RANI | → 0 | Neutral | 7.884.709 $ | +1.638.909 $ | +26,2 % | 1 | 6.245.800 $ | -5.229.200 $ | -45,6 % | 1 | 11.475.000 $ | +11.475.000 $ | 1 | |
| PALVELLA THERAPEUTICS, INC. | PVLA | → 0 | Schwach | 4.790.549 $ | -6.180.646 $ | -56,3 % | 1 | 10.971.195 $ | -2.170.760 $ | -16,5 % | 1 | ||||
| Abivax S.A. | ABVX | → 0 | Neutral | 7.341.960 $ | +1.041.666 $ | +16,5 % | 1 | 6.300.294 $ | -3.873.437 $ | -38,1 % | 1 | 10.173.731 $ | +3.768.705 $ | +58,8 % | 1 |
| Nkarta, Inc. | NKTX | → 0 | Neutral | 9.926.695 $ | +2.525.520 $ | +34,1 % | 1 | 7.401.175 $ | +911.993 $ | +14,1 % | 1 | 6.489.182 $ | -1.310.650 $ | -16,8 % | 1 |
| Artiva Biotherapeutics, Inc. | ARTV | → 0 | Schwach | 9.262.152 $ | +9.262.152 $ | 1 | |||||||||
| X4 Pharmaceuticals, Inc | XFOR | → 0 | Neutral | 6.517.391 $ | -1.051.107 $ | -13,9 % | 1 | 7.568.498 $ | -271.502 $ | -3,5 % | 1 | 7.840.000 $ | +7.840.000 $ | 1 | |
| AgomAb Therapeutics NV | AGMB | → 0 | Neutral | 7.788.000 $ | +1.494.000 $ | +23,7 % | 1 | 6.294.000 $ | +6.294.000 $ | 1 | |||||
| Arcellx, Inc. | ACLX | → 0 | 6.989.438 $ | +3.020.518 $ | +76,1 % | 1 | 3.968.920 $ | -2.694.727 $ | -40,4 % | 1 | |||||
| Coherus Oncology, Inc. | CHRS | → 0 | Neutral | 4.799.999 $ | -994.286 $ | -17,2 % | 1 | 5.794.285 $ | +5.794.285 $ | 1 | |||||
| Eloxx Pharmaceuticals, Inc. | ELOX | → 0 | Neutral | 5.552.000 $ | +5.552.000 $ | 1 | |||||||||
| Contineum Therapeutics, Inc. | CTNM | → 0 | Neutral | 825.760 $ | -5.885.159 $ | -87,7 % | 1 | ||||||||
| Nuvation Bio Inc. | NUVB | → 0 | Schwach | 40.959 $ | +14.012 $ | +52,0 % | 1 | ||||||||
| Gesamt | 1.217.462.122 $ | +200.139.003 $ | +3,9 % | 24 | 1.029.103.106 $ | +60.712.831 $ | +45,8 % | 22 | 969.256.994 $ | +244.234.416 $ | +36,8 % | 21 | |||